ARK's Portfolio Pivot: Dumping Social Media Baggage for a Shot of Medical AI

ARK Invest has been busy at the trading terminal, giving its flagship ETFs a shake-up that involved lightening up on big tech and placing a hefty wager on the future of healthcare AI. It seems even Cathie Wood's crystal ball needs the occasional recalibration.

The firm decided to offload 3,578 Meta shares across three of its funds, a sale worth approximately $2.1 million. This leaves the ARK Innovation ETF holding a still-respectable 105,000 Meta shares, valued near $63 million, which is about 1% of the fund's total assets. The timing is, as they say in the biz, not a coincidence, coming hot on the heels of a jury finding Meta and Google's YouTube negligent in a social-media addiction case—both companies plan to appeal. In a classic case of corporate multitasking, Meta also unveiled a new executive pay plan aiming for a 500% stock moonshot and a potential $9 trillion valuation by 2031, all while quietly confirming layoffs of several hundred employees. Meta's stock, perhaps weighed down by the drama, managed a meager 0.3% gain for the day.

Not stopping at Meta, ARK also cashed out 95,090 shares of Roku across its ARKK, ARKW, and ARKF funds, pocketing around $9.1 million. The sell-off continued with a clearance sale of other positions: 30,174 shares of Teradyne for roughly $9.7 million, 205,019 shares of Bullish for about $7.7 million, 62,393 shares of Kratos Defense for approximately $4.8 million, and 27,647 shares of Natera worth around $5.4 million. When Cathie trims, she doesn't mess around.

On the flip side, ARK went shopping for 84,939 shares of Tempus AI through its ARKK and ARKG ETFs, deploying about $4.1 million. This buy-the-dip maneuver happened as the stock itself dipped 4.2% on Wednesday and is currently down 21% for the year 2026—a classic "high-conviction" play that would make any degen nod in respect. The ARK Innovation ETF now boasts a hefty bag of around 6.3 million Tempus AI shares, worth over $294 million, catapulting it to the fund's third-largest holding, right behind Tesla and Crispr Therapeutics and accounting for roughly 5% of the entire portfolio.

So, what's the big buy? Tempus AI is a healthcare tech firm that uses artificial intelligence to wrangle and make sense of complex medical data, with a sharp focus on improving cancer care. It's betting that algorithms can be better at pattern recognition than your average overworked oncologist.

The Wednesday shopping spree also included smaller baskets of shares in Archer Aviation and Beam Therapeutics. For what it's worth, the ARK Innovation ETF itself closed the day up 1.3%, perhaps breathing a sigh of relief after the rebalancing workout. Recent transaction logs show ARK has been consistently scaling back its bags in Roku, Teradyne, and Bullish while steadily accumulating its Tempus AI position over several days, proving that even prophetic investors sometimes dollar-cost average.